Bioaffinity Technologies, Inc.2024财年第二财季实现净利润-2.11百万美元，同比减少21.26%

自选股智能写手08-19

8月19日，Bioaffinity Technologies, Inc.（BIAF.US）公布财报，公告显示公司2024财年第二财季净利润为-2.11百万美元，同比减少21.26%；其中营业收入为2.40百万美元，同比增加12059.29%，每股基本收益为-0.19美元。从资产负债表来看，Bioaffinity Technologies, Inc.（BIAF.US）总负债3.22百万美元，其中短期...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2460710856?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-19 00:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2460710856","market":"us","top_or_hot":-1,"title":"Bioaffinity Technologies, Inc.2024财年第二财季实现净利润-2.11百万美元，同比减少21.26%","media":"自选股智能写手","content":"<div>\n<p>8月19日，Bioaffinity Technologies, Inc.（BIAF.US）公布财报，公告显示公司2024财年第二财季净利润为-2.11百万美元，同比减少21.26%；其中营业收入为2.40百万美元，同比增加12059.29%，每股基本收益为-0.19美元。从资产负债表来看，Bioaffinity Technologies, Inc.（BIAF.US）总负债3.22百万美元，其中短期...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408190001489f363ba0&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bioaffinity Technologies, Inc.2024财年第二财季实现净利润-2.11百万美元，同比减少21.26%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioaffinity Technologies, Inc.2024财年第二财季实现净利润-2.11百万美元，同比减少21.26%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-19 00:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408190001489f363ba0&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月19日，Bioaffinity Technologies, Inc.（BIAF.US）公布财报，公告显示公司2024财年第二财季净利润为-2.11百万美元，同比减少21.26%；其中营业收入为2.40百万美元，同比增加12059.29%，每股基本收益为-0.19美元。从资产负债表来看，Bioaffinity Technologies, Inc.（BIAF.US）总负债3.22百万美元，其中短期...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408190001489f363ba0&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIAF","symbol_name":"bioAffinity Technologies, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408190001489f363ba0&s=b","article_id":"2460710856","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408190001489f363ba0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2460710856","pubTimestamp":1723996896,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"8月19日，Bioaffinity Technologies, Inc.公布财报，公告显示公司2024财年第二财季净利润为-2.11百万美元，同比减少21.26%；其中营业收入为2.40百万美元，同比增加12059.29%，每股基本收益为-0.19美元。从资产负债表来看，Bioaffinity Technologies, Inc.总负债3.22百万美元，其中短期债务482958.00美元，资产负债比为2.07，流动比率为1.16。机构评级：截至2024年8月19日，当前有1家机构对Bioaffinity Technologies, Inc.目标价做出预测，其中目标均价为6.00美元，其中最低目标价为6.00美元，最高目标价为6.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"BIAF":"bioAffinity Technologies, Inc."},"translate_title":"Bioaffinity Technologies, Inc. achieved net profit of-US $2.11 million in the second fiscal quarter of fiscal 2024, a year-on-year decrease of 21.26%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIAF":0.9},"content_text":"8月19日，Bioaffinity Technologies, Inc.（BIAF.US）公布财报，公告显示公司2024财年第二财季净利润为-2.11百万美元，同比减少21.26%；其中营业收入为2.40百万美元，同比增加12059.29%，每股基本收益为-0.19美元。从资产负债表来看，Bioaffinity Technologies, Inc.（BIAF.US）总负债3.22百万美元，其中短期债务482958.00美元，资产负债比为2.07，流动比率为1.16。机构评级：截至2024年8月19日，当前有1家机构对Bioaffinity Technologies, Inc.目标价做出预测，其中目标均价为6.00美元，其中最低目标价为6.00美元，最高目标价为6.00美元。公司简介：bioAffinity Technologies Inc 致力于解决早期癌症和肺部疾病无创诊断以及靶向癌症治疗的需求。公司使用能够优先靶向癌细胞和指示疾病状态的细胞群体的技术开发专有的无创诊断测试和癌症治疗药物。公司的产品CyPath Lung是一种用于检测早期肺癌的无创测试。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2460710856"}